This is a Validated Antibody Database (VAD) review about human CTLA 4, based on 66 published articles (read how Labome selects the articles), using CTLA 4 antibody in all methods. It is aimed to help Labome visitors find the most suited CTLA 4 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
CTLA 4 synonym: ALPS5; CD; CD152; CELIAC3; CTLA-4; GRD4; GSE; IDDM12

BioLegend
mouse monoclonal (BNI3)
  • other; mouse
BioLegend CTLA 4 antibody (BioLegend, BNI3) was used in other on mouse samples . Nat Commun (2020) ncbi
mouse monoclonal (L3D10)
  • flow cytometry; human; loading ...; fig 4a
BioLegend CTLA 4 antibody (Biolegend, L3D10) was used in flow cytometry on human samples (fig 4a). Arthritis Res Ther (2020) ncbi
mouse monoclonal (L3D10)
  • mass cytometry; human; loading ...; fig 2b
BioLegend CTLA 4 antibody (Biolegend, 349902) was used in mass cytometry on human samples (fig 2b). Cell (2019) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 5a
BioLegend CTLA 4 antibody (BioLegend, BNI3) was used in flow cytometry on human samples (fig 5a). J Exp Med (2018) ncbi
mouse monoclonal (L3D10)
  • flow cytometry; human; loading ...; fig 2b,2c
In order to elucidate the interaction between tumor-associated and -infiltrating lymphocytes in ovarian cancer, BioLegend CTLA 4 antibody (Biolegend, 349913) was used in flow cytometry on human samples (fig 2b,2c). Oncoimmunology (2017) ncbi
mouse monoclonal (L3D10)
  • flow cytometry; human
In order to characterize activated T cells in joint tissue from patients with rheumatoid arthritis, BioLegend CTLA 4 antibody (biolegend, L3D10) was used in flow cytometry on human samples . Nature (2017) ncbi
mouse monoclonal (L3D10)
  • flow cytometry; human; fig 5
In order to discuss the use of natural killer cells for clinical applications, BioLegend CTLA 4 antibody (BioLegend, L3D10) was used in flow cytometry on human samples (fig 5). Cytotherapy (2017) ncbi
mouse monoclonal (L3D10)
  • flow cytometry; human; loading ...; fig s3
BioLegend CTLA 4 antibody (Biolegend, L3D10) was used in flow cytometry on human samples (fig s3). Nature (2016) ncbi
mouse monoclonal (L3D10)
  • flow cytometry; human; loading ...; fig 3
In order to study the pharmacologic inhibition of PI3K and MEK pathways in mixed cultures of human mononuclear cells., BioLegend CTLA 4 antibody (BioLegend, L3D10) was used in flow cytometry on human samples (fig 3). Am J Transplant (2016) ncbi
mouse monoclonal (L3D10)
  • flow cytometry; human; fig 3c
In order to assess the impact of neoantigen intratumor heterogeneity on antitumor immunity, BioLegend CTLA 4 antibody (Biolegend, L3D10) was used in flow cytometry on human samples (fig 3c). Science (2016) ncbi
mouse monoclonal (L3D10)
  • flow cytometry; human; loading ...; fig 3b
In order to demonstrate that TGF-beta induces the differentiation of human CXCL13-producing CD4 positive T cells from naive CD4 positive T cells, BioLegend CTLA 4 antibody (BioLegend, L3D10) was used in flow cytometry on human samples (fig 3b). Eur J Immunol (2016) ncbi
mouse monoclonal (L3D10)
  • flow cytometry; human; fig 5
BioLegend CTLA 4 antibody (Biolegend, L3D10) was used in flow cytometry on human samples (fig 5). J Autoimmun (2015) ncbi
mouse monoclonal (L3D10)
  • flow cytometry; human
In order to determine the presence, frequency, association to other immune parameters, and functional properties of circulating CD14(+) cells lacking HLA-DR expression in patients with untreated chronic lymphocytic leukemia, BioLegend CTLA 4 antibody (Biolegend, L3D10) was used in flow cytometry on human samples . Blood (2014) ncbi
Invitrogen
mouse monoclonal (14D3)
  • flow cytometry; human; loading ...; fig s3
Invitrogen CTLA 4 antibody (eBioscience, 14D3) was used in flow cytometry on human samples (fig s3). Eur J Immunol (2019) ncbi
mouse monoclonal (14D3)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
  • western blot; human; loading ...; fig s1
In order to investigate the expression of CTLA-4 in the non-small cell lung cancer and its prognostic impact, Invitrogen CTLA 4 antibody (eBioscience, 14-1529) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1) and in western blot on human samples (fig s1). Cancer Immunol Immunother (2017) ncbi
mouse monoclonal (14D3)
  • immunohistochemistry - frozen section; human; loading ...; fig 5b
In order to describe and evaluate pituitary glands from cancer patients treated with CTLA-4 blockade, Invitrogen CTLA 4 antibody (eBioscience, 14D3) was used in immunohistochemistry - frozen section on human samples (fig 5b). Am J Pathol (2016) ncbi
mouse monoclonal (14D3)
  • flow cytometry; human; loading ...; fig 3c
In order to report that patients with PTEN mutations experience autoimmunity and lymphoid hyperplasia, Invitrogen CTLA 4 antibody (eBioscience, 14D3) was used in flow cytometry on human samples (fig 3c). J Allergy Clin Immunol (2017) ncbi
mouse monoclonal (14D3)
  • flow cytometry; rhesus macaque; fig 2
Invitrogen CTLA 4 antibody (eBioscience, 46-1529) was used in flow cytometry on rhesus macaque samples (fig 2). Nat Commun (2015) ncbi
mouse monoclonal (14D3)
  • flow cytometry; human; fig 7
Invitrogen CTLA 4 antibody (eBioscience, 14D3) was used in flow cytometry on human samples (fig 7). Haematologica (2016) ncbi
mouse monoclonal (14D3)
  • flow cytometry; human
In order to learn about stoichiometry of membrane proteins by single-molecule localization microscopy, Invitrogen CTLA 4 antibody (eBioscience, 14D3) was used in flow cytometry on human samples . Sci Rep (2015) ncbi
mouse monoclonal (14D3)
  • blocking or activating experiments; human; fig 7
Invitrogen CTLA 4 antibody (eBioscience, 14D3) was used in blocking or activating experiments on human samples (fig 7). Nat Commun (2015) ncbi
mouse monoclonal (14D3)
  • flow cytometry; human
Invitrogen CTLA 4 antibody (eBioscience, 14D3) was used in flow cytometry on human samples . Hum Immunol (2015) ncbi
mouse monoclonal (14D3)
  • flow cytometry; human
Invitrogen CTLA 4 antibody (eBioscience, 14D3) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (14D3)
  • flow cytometry; human
In order to developed a strategy to expand umbilical cord blood T cells and test their effects after transplantation, Invitrogen CTLA 4 antibody (eBioscience, 14D3) was used in flow cytometry on human samples . Leukemia (2015) ncbi
Santa Cruz Biotechnology
mouse monoclonal (F-8)
  • immunohistochemistry; mouse; 1:5000; loading ...; fig 7d
Santa Cruz Biotechnology CTLA 4 antibody (Santa Cruz Biotechnology, sc-376016) was used in immunohistochemistry on mouse samples at 1:5000 (fig 7d). JCI Insight (2020) ncbi
mouse monoclonal (F-8)
  • flow cytometry; mouse; loading ...; fig 1b
Santa Cruz Biotechnology CTLA 4 antibody (Santa Cruz, sc-376016) was used in flow cytometry on mouse samples (fig 1b). Braz J Med Biol Res (2016) ncbi
mouse monoclonal (F-8)
  • immunohistochemistry - paraffin section; human; 1:300; loading ...; fig 3c
Santa Cruz Biotechnology CTLA 4 antibody (Santa Cruz, sc-376016) was used in immunohistochemistry - paraffin section on human samples at 1:300 (fig 3c). J Immunol Res (2016) ncbi
mouse monoclonal (F-8)
  • immunohistochemistry - paraffin section; human; 1:50; fig 2
Santa Cruz Biotechnology CTLA 4 antibody (Santa Cruz, SC-376016) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 2). Breast Cancer Res (2016) ncbi
mouse monoclonal (F-8)
  • immunohistochemistry - paraffin section; human; 1:400; tbl 4
In order to test if atypical fibroxanthoma is the non-infiltrating precursor lesion of pleomorphic dermal sarcoma, Santa Cruz Biotechnology CTLA 4 antibody (Santa Cruz, sc-376016) was used in immunohistochemistry - paraffin section on human samples at 1:400 (tbl 4). Oncotarget (2016) ncbi
Abcam
domestic rabbit monoclonal (EPR1476)
  • western blot; mouse; fig 12
In order to determine the induction of liver injury in mice due to molecular circuits of diclofenac revealed by immunogenomics, Abcam CTLA 4 antibody (Abcam, ab134090) was used in western blot on mouse samples (fig 12). Oncotarget (2016) ncbi
Abnova
mouse monoclonal (2F1)
  • immunocytochemistry; human; 1:100; fig 1
Abnova CTLA 4 antibody (Abnova, H00001493-M06) was used in immunocytochemistry on human samples at 1:100 (fig 1). EJNMMI Res (2016) ncbi
BD Biosciences
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...
BD Biosciences CTLA 4 antibody (BD Biosciences, 555853) was used in flow cytometry on human samples . J Clin Invest (2020) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 2e
BD Biosciences CTLA 4 antibody (BD Biosciences, 555854) was used in flow cytometry on human samples (fig 2e). Cell (2020) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 5s1e
BD Biosciences CTLA 4 antibody (BD, 560938) was used in flow cytometry on human samples (fig 5s1e). elife (2019) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 1f
BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in flow cytometry on human samples (fig 1f). Proc Natl Acad Sci U S A (2019) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig s3a
BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in flow cytometry on human samples (fig s3a). Cancer (2019) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; rhesus macaque; loading ...; fig 4a
BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in flow cytometry on rhesus macaque samples (fig 4a). J Virol (2019) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 3f
BD Biosciences CTLA 4 antibody (BD, BNI3) was used in flow cytometry on human samples (fig 3f). J Clin Invest (2018) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 3d
BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in flow cytometry on human samples (fig 3d). J Exp Med (2018) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 5a
BD Biosciences CTLA 4 antibody (BD Pharmingen, BNI3) was used in flow cytometry on human samples (fig 5a). Sci Rep (2017) ncbi
mouse monoclonal (BNI3)
  • mass cytometry; human; loading ...; fig 2a
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, BD Biosciences CTLA 4 antibody (BD Biosciences, BN13) was used in mass cytometry on human samples (fig 2a). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 1c
In order to characterize CD8 T cells isolated patients with stage IV melanoma before and after treatment with pembrolizumab, BD Biosciences CTLA 4 antibody (BD, BNI3) was used in flow cytometry on human samples (fig 1c). Nature (2017) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig s2b
BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in flow cytometry on human samples (fig s2b). Immun Ageing (2017) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 2
In order to examine the potential of IL-2 to enhance T regulatory cell therapy, BD Biosciences CTLA 4 antibody (BD Biosciences, BN13) was used in flow cytometry on human samples (fig 2). Clin Exp Immunol (2017) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; rhesus macaque; loading ...; fig 4b
In order to study CXCR5+ CD8 T cells in SIV-infected animals, BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in flow cytometry on rhesus macaque samples (fig 4b). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 2e
In order to observe that the use of chimeric antigen receptor technology is a clinically applicable refinement of regulatory T cell therapy for organ transplantation, BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in flow cytometry on human samples (fig 2e). Am J Transplant (2017) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 6d
BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in flow cytometry on human samples (fig 6d). Cell Death Dis (2016) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; tbl 1
In order to demonstrate that freezing already-stained samples suspended in 10% DMSO in FBS is practical and efficient way to preserve already-stained samples for mass cytometry assessment, BD Biosciences CTLA 4 antibody (BD Biosciences, BN13) was used in flow cytometry on human samples (tbl 1). Cytometry A (2017) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; tbl 3
BD Biosciences CTLA 4 antibody (BD Pharmingen, BNI3) was used in flow cytometry on human samples (tbl 3). Brain Behav (2016) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...
In order to establish the T Cell receptor-inducible costimulator as a promising target for direct T regulatory cell-targeting therapeutic agents for gastric cancer, BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in flow cytometry on human samples . Int J Cancer (2017) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig s3a
In order to identify and characterize CXCR5hiCD44hiCD8 T cells in HIV-infected individuals, BD Biosciences CTLA 4 antibody (BD, 561717) was used in flow cytometry on human samples (fig s3a). PLoS Pathog (2016) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; fig 1
In order to test if CD4 positive T cells expressing immune checkpoint molecules are enriched in HIV-infected cells in patients receiving antiretroviral therapy, BD Biosciences CTLA 4 antibody (BD, 555853) was used in flow cytometry on human samples (fig 1). PLoS Pathog (2016) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; fig s1
In order to develop an HLA-A2-specific chimeric antigen receptor and use it to generate alloantigen-specific human T regulatory cells, BD Biosciences CTLA 4 antibody (BD Biosciences, 555855) was used in flow cytometry on human samples (fig s1). J Clin Invest (2016) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; fig st1
In order to find cell-surface markers specific to human neutrophils, BD Biosciences CTLA 4 antibody (BD, 555853) was used in flow cytometry on human samples (fig st1). Exp Cell Res (2016) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human
BD Biosciences CTLA 4 antibody (BD PharMingen, 555855) was used in flow cytometry on human samples . Immunity (2016) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; African green monkey; fig 1
In order to study lymph node-resident simian immunodeficiency virus env-specific T follicular helper cells due to vaccine induction in Rhesus Macaques, BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in flow cytometry on African green monkey samples (fig 1). J Immunol (2016) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; fig 1a
In order to analyze HIV progression traits of a selective loss of early differentiated and highly functional PD1high CD4 T cells, BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in flow cytometry on human samples (fig 1a). PLoS ONE (2015) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; fig 2
BD Biosciences CTLA 4 antibody (BD Biosciences, 555853) was used in flow cytometry on human samples (fig 2). Retrovirology (2015) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 1b,e
In order to look at patterns of S. Typhi-specific modulation of the homing potential of circulating Treg in patients with typhoid compared to healthy individuals, BD Biosciences CTLA 4 antibody (BD, 561717) was used in flow cytometry on human samples (fig 1b,e). PLoS Pathog (2015) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human
BD Biosciences CTLA 4 antibody (BD, 555855) was used in flow cytometry on human samples . Cytometry A (2015) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human
BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in flow cytometry on human samples . PLoS ONE (2015) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human; loading ...; fig 1
In order to investigate the role of granzyme B in T regulatory cell resistance, BD Biosciences CTLA 4 antibody (BD Biosciences, BN13) was used in flow cytometry on human samples (fig 1). J Immunol (2015) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; African green monkey; fig s4a
In order to describe the functional characteristics and dynamics of T cells in individual granulomas, BD Biosciences CTLA 4 antibody (BD Pharmigen, BN13) was used in flow cytometry on African green monkey samples (fig s4a). PLoS Pathog (2015) ncbi
mouse monoclonal (BNI3)
  • flow cytometry; human
BD Biosciences CTLA 4 antibody (BD, BNI3) was used in flow cytometry on human samples . J Immunol (2015) ncbi
mouse monoclonal (BNI3)
  • immunocytochemistry; human
BD Biosciences CTLA 4 antibody (BD Biosciences, BNI3) was used in immunocytochemistry on human samples . Eur J Immunol (2014) ncbi
mouse monoclonal (BNI3)
  • western blot; human; fig 3
BD Biosciences CTLA 4 antibody (BD Biosciences, 555853) was used in western blot on human samples (fig 3). Mol Cell Biol (2014) ncbi
Articles Reviewed
  1. Tseng H, Xiong W, Badeti S, Yang Y, Ma M, Liu T, et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11:4810 pubmed publisher
  2. Tan E, Hopkins R, Lim C, Jamuar S, Ong C, Thoon K, et al. Dominant-negative NFKBIA mutation promotes IL-1β production causing hepatic disease with severe immunodeficiency. J Clin Invest. 2020;130:5817-5832 pubmed publisher
  3. Pasciuto E, Burton O, Roca C, Lagou V, Rajan W, Theys T, et al. Microglia Require CD4 T Cells to Complete the Fetal-to-Adult Transition. Cell. 2020;182:625-640.e24 pubmed publisher
  4. Li H, Lu C, Zhang H, Hu Q, Zhang J, Cuevas I, et al. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight. 2020;5: pubmed publisher
  5. Hanaoka H, Nishimoto T, Okazaki Y, Takeuchi T, Kuwana M. A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. Arthritis Res Ther. 2020;22:88 pubmed publisher
  6. Pech M, Fong L, Villalta J, Chan L, Kharbanda S, O Brien J, et al. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. elife. 2019;8: pubmed publisher
  7. Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed publisher
  8. Remmerswaal E, Hombrink P, Nota B, Pircher H, ten Berge I, van Lier R, et al. Expression of IL-7Rα and KLRG1 defines functionally distinct CD8+ T-cell populations in humans. Eur J Immunol. 2019;49:694-708 pubmed publisher
  9. Ha D, Tanaka A, Kibayashi T, Tanemura A, Sugiyama D, Wing J, et al. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc Natl Acad Sci U S A. 2019;116:609-618 pubmed publisher
  10. Williams P, Basu S, Garcia Manero G, Hourigan C, Oetjen K, Cortes J, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470-1481 pubmed publisher
  11. Hoang T, Harper J, Pino M, Wang H, Micci L, King C, et al. Bone Marrow-Derived CD4+ T Cells Are Depleted in Simian Immunodeficiency Virus-Infected Macaques and Contribute to the Size of the Replication-Competent Reservoir. J Virol. 2019;93: pubmed publisher
  12. Petrelli A, Mijnheer G, Hoytema van Konijnenburg D, van der Wal M, Giovannone B, Mocholí E, et al. PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation. J Clin Invest. 2018;128:4669-4681 pubmed publisher
  13. Sayin I, Radtke A, Vella L, Jin W, Wherry E, Buggert M, et al. Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med. 2018;215:1531-1542 pubmed publisher
  14. Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells. J Exp Med. 2018;215:985-997 pubmed publisher
  15. Liaskou E, Jeffery L, Chanouzas D, Soskic B, Seldin M, Harper L, et al. Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals. Sci Rep. 2017;7:7652 pubmed publisher
  16. Paulsen E, Kilvaer T, Rakaee M, Richardsen E, Hald S, Andersen S, et al. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunol Immunother. 2017;66:1449-1461 pubmed publisher
  17. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed publisher
  18. Huang A, Postow M, Orlowski R, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60-65 pubmed publisher
  19. van der Geest K, Wang Q, Eijsvogels T, Koenen H, Joosten I, Brouwer E, et al. Changes in peripheral immune cell numbers and functions in octogenarian walkers - an acute exercise study. Immun Ageing. 2017;14:5 pubmed publisher
  20. Huang R, Francois A, McGray A, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561 pubmed publisher
  21. Jeffery H, Jeffery L, Lutz P, Corrigan M, Webb G, Hirschfield G, et al. Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin Exp Immunol. 2017;188:394-411 pubmed publisher
  22. Mylvaganam G, Rios D, Abdelaal H, Iyer S, Tharp G, Mavigner M, et al. Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection. Proc Natl Acad Sci U S A. 2017;114:1976-1981 pubmed publisher
  23. Rao D, Gurish M, Marshall J, Slowikowski K, Fonseka C, Liu Y, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542:110-114 pubmed publisher
  24. Boardman D, Philippeos C, Fruhwirth G, Ibrahim M, Hannen R, Cooper D, et al. Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection. Am J Transplant. 2017;17:931-943 pubmed publisher
  25. Wei C, Mei J, Tang L, Liu Y, Li D, Li M, et al. 1-Methyl-tryptophan attenuates regulatory T cells differentiation due to the inhibition of estrogen-IDO1-MRC2 axis in endometriosis. Cell Death Dis. 2016;7:e2489 pubmed publisher
  26. Oelsner S, Friede M, Zhang C, Wagner J, Badura S, Bader P, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017;19:235-249 pubmed publisher
  27. Sumatoh H, Teng K, Cheng Y, Newell E. Optimization of mass cytometry sample cryopreservation after staining. Cytometry A. 2017;91:48-61 pubmed publisher
  28. Mai T, Ma R, Li Z, Bi S. Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer. Braz J Med Biol Res. 2016;49:e5620 pubmed publisher
  29. Dyer W, Tan J, Day T, Kiers L, Kiernan M, Yiannikas C, et al. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. Brain Behav. 2016;6:e00516 pubmed
  30. Kaewkangsadan V, Verma C, Eremin J, Cowley G, Ilyas M, Eremin O. Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. J Immunol Res. 2016;2016:4757405 pubmed
  31. Nagase H, Takeoka T, Urakawa S, Morimoto Okazawa A, Kawashima A, Iwahori K, et al. ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017;140:686-695 pubmed publisher
  32. Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman H, Larman T, et al. Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. Am J Pathol. 2016;186:3225-3235 pubmed publisher
  33. Miles B, Miller S, Folkvord J, Levy D, Rakasz E, Skinner P, et al. Follicular Regulatory CD8 T Cells Impair the Germinal Center Response in SIV and Ex Vivo HIV Infection. PLoS Pathog. 2016;12:e1005924 pubmed publisher
  34. Chen H, Händel N, Ngeow J, Muller J, Huhn M, Yang H, et al. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol. 2017;139:607-620.e15 pubmed publisher
  35. Fromentin R, Bakeman W, Lawani M, Khoury G, Hartogensis W, DaFonseca S, et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathog. 2016;12:e1005761 pubmed publisher
  36. Ruibal P, Oestereich L, Lüdtke A, Becker Ziaja B, Wozniak D, Kerber R, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature. 2016;533:100-4 pubmed publisher
  37. Duchnowska R, Pęksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, et al. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res. 2016;18:43 pubmed publisher
  38. Zwang N, Zhang R, Germana S, Fan M, Hastings W, Cao A, et al. Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways. Am J Transplant. 2016;16:2624-38 pubmed publisher
  39. Macdonald K, Hoeppli R, Huang Q, Gillies J, Luciani D, Orban P, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126:1413-24 pubmed publisher
  40. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher
  41. Helbig D, Ihle M, Pütz K, Tantcheva Poor I, Mauch C, Büttner R, et al. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget. 2016;7:21763-74 pubmed publisher
  42. McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-9 pubmed publisher
  43. Lee E, Oh J, Selvaraj S, Park S, Choi M, Spanel R, et al. Immunogenomics reveal molecular circuits of diclofenac induced liver injury in mice. Oncotarget. 2016;7:14983-5017 pubmed publisher
  44. Procaccini C, Carbone F, Di Silvestre D, Brambilla F, De Rosa V, Galgani M, et al. The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements. Immunity. 2016;44:406-21 pubmed publisher
  45. Vargas Inchaustegui D, Demers A, Shaw J, Kang G, Ball D, Tuero I, et al. Vaccine Induction of Lymph Node-Resident Simian Immunodeficiency Virus Env-Specific T Follicular Helper Cells in Rhesus Macaques. J Immunol. 2016;196:1700-10 pubmed publisher
  46. Meletta R, Müller Herde A, Dennler P, Fischer E, Schibli R, Krämer S. Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis. EJNMMI Res. 2016;6:1 pubmed publisher
  47. Paris R, Petrovas C, Ferrando Martinez S, Moysi E, Boswell K, Archer E, et al. Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression. PLoS ONE. 2015;10:e0144767 pubmed publisher
  48. Kobayashi S, Watanabe T, Suzuki R, Furu M, Ito H, Ito J, et al. TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells. Eur J Immunol. 2016;46:360-71 pubmed publisher
  49. Miles B, Miller S, Folkvord J, Kimball A, Chamanian M, Meditz A, et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat Commun. 2015;6:8608 pubmed publisher
  50. Scottà C, Fanelli G, Hoong S, Romano M, Lamperti E, Sukthankar M, et al. Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica. 2016;101:91-100 pubmed publisher
  51. Heigele A, Joas S, Regensburger K, Kirchhoff F. Increased susceptibility of CD4+ T cells from elderly individuals to HIV-1 infection and apoptosis is associated with reduced CD4 and enhanced CXCR4 and FAS surface expression levels. Retrovirology. 2015;12:86 pubmed publisher
  52. Fricke F, Beaudouin J, Eils R, Heilemann M. One, two or three? Probing the stoichiometry of membrane proteins by single-molecule localization microscopy. Sci Rep. 2015;5:14072 pubmed publisher
  53. McArthur M, Fresnay S, Magder L, Darton T, Jones C, Waddington C, et al. Activation of Salmonella Typhi-specific regulatory T cells in typhoid disease in a wild-type S. Typhi challenge model. PLoS Pathog. 2015;11:e1004914 pubmed publisher
  54. Inglis H, Danesh A, Shah A, Lacroix J, Spinella P, Norris P. Techniques to improve detection and analysis of extracellular vesicles using flow cytometry. Cytometry A. 2015;87:1052-63 pubmed publisher
  55. Yukl S, Shergill A, Girling V, Li Q, Killian M, Epling L, et al. Site-specific differences in T cell frequencies and phenotypes in the blood and gut of HIV-uninfected and ART-treated HIV+ adults. PLoS ONE. 2015;10:e0121290 pubmed publisher
  56. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell L, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692 pubmed publisher
  57. Nouël A, Pochard P, Simon Q, Ségalen I, Le Meur Y, Pers J, et al. B-Cells induce regulatory T cells through TGF-β/IDO production in A CTLA-4 dependent manner. J Autoimmun. 2015;59:53-60 pubmed publisher
  58. Bhela S, Kempsell C, Manohar M, Dominguez Villar M, Griffin R, Bhatt P, et al. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol. 2015;194:2180-9 pubmed publisher
  59. Gideon H, Phuah J, Myers A, Bryson B, Rodgers M, Coleman M, et al. Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLoS Pathog. 2015;11:e1004603 pubmed publisher
  60. Rueda C, Wells C, Gisslen T, Jobe A, Kallapur S, Chougnet C. Effect of chorioamnionitis on regulatory T cells in moderate/late preterm neonates. Hum Immunol. 2015;76:65-73 pubmed publisher
  61. Huss D, Mehta D, Sharma A, You X, Riester K, Sheridan J, et al. In vivo maintenance of human regulatory T cells during CD25 blockade. J Immunol. 2015;194:84-92 pubmed
  62. Bending D, Pesenacker A, Ursu S, Wu Q, Lom H, Thirugnanabalan B, et al. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol. 2014;193:2699-708 pubmed publisher
  63. Pegram H, Purdon T, van Leeuwen D, Curran K, Giralt S, Barker J, et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015;29:415-22 pubmed publisher
  64. Jitschin R, Braun M, Büttner M, Dettmer Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750-60 pubmed publisher
  65. Gautron A, Dominguez Villar M, de Marcken M, Hafler D. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur J Immunol. 2014;44:2703-2711 pubmed publisher
  66. Kloog Y, Mor A. Cytotoxic-T-lymphocyte antigen 4 receptor signaling for lymphocyte adhesion is mediated by C3G and Rap1. Mol Cell Biol. 2014;34:978-88 pubmed publisher